The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).
The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
SOHO 2024 | Key considerations when deploying bispecific antibodies for the treatment of B-cell malignancies
Muhammad Bilal Abid, MD, UT Houston McGovern School of Medicine, Houston, TX, discusses important considerations for the deployment of bispecific antibodies into the community for the treatment of various B-cell malignancies. He highlights the importance of considering treatment duration, route of administration, patient characteristics, and infection risk to select the most appropriate agent for individual patients. This interview took place at the Twelfth Annual Meeting of the Society of Hematologic Oncology (SOHO 2024) congress in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
